<DOC>
	<DOCNO>NCT00412334</DOCNO>
	<brief_summary>This study evaluate efficacy safety 4 regimen PEGASYS plus Copegus , patient chronic hepatitis C ( CHC ) genotype 1 fail respond previous treatment standard dose PEGASYS plus ribavirin . Patients randomize one 4 group , receive ) PEGASYS 360 micrograms/week plus Copegus 1000-1200mg/day , b ) PEGASYS 180 microgram twice weekly plus Copegus 1000-1200mg/day , c ) PEGASYS 360micrograms/week plus Copegus 1200-1600mg/day , ) PEGASYS 180 microgram twice weekly plus Copegus 1200-1600mg/day . Following 48 week treatment , 24 week period treatment-free follow-up . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>SYREN Study : A Study PEGASYS ( Peginterferon Alfa-2a ( 40KD ) ) Plus Copegus ( Ribavirin ) Non-Responder Patients With Chronic Hepatitis C ( CHC ) Genotype 1 .</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>adult patient &gt; =18 year age , CHC genotype 1 ; patient fail respond previous treatment PEGASYS plus ribavirin &gt; =12 week ; patient discontinue PEGASYS/ribavirin &gt; =4 week prior enrollment ; compensate liver disease . form liver disease ; infection HIV , HAV , HBV ; hepatocellular cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>